Children, Teens, and Adults with Severe Asthma

For some people with asthma, symptoms are not well controlled on current medications. These studies are researching an investigational medication for patients with uncontrolled or severe asthma. The study drug is being tested to determine if it can reduce inflammation in patients' airways, improve asthma symptoms and decrease the number of asthma attacks.

Line art illustration of lungs

Check eligibility?

Study details

Study details

Drug
QAW039/fevipiprant

Phase
Phase 3

Number of participants
765 participants in the US

Duration
This trial is up to 64 weeks long, requiring up to 11 visits, up to 6 telephone visits, and no overnight stays.

Is a placebo being used?
Yes

Sponsored by:
Novartis

Will the results of this trial be published?
Yes

Will patients be able to continue taking the medication after the trial?
No

Costs
All study related medications and procedures will be provided.

If you would like to speak to someone regarding this trial, first check to see if you are eligible above. If it seems that you are eligible to take part, you will be contacted by phone, and you will be able to ask any additional questions you may have about this clinical trial.

English (US)

Español (US)